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Abstract
Replication of many RNA viruses is accompanied by extensive remodeling of intracellular membranes. In poliovirus-infected
cells, ER and Golgi stacks disappear, while new clusters of vesicle-like structures form sites for viral RNA synthesis. Virus
replication is inhibited by brefeldin A (BFA), implicating some components(s) of the cellular secretory pathway in virus
growth. Formation of characteristic vesicles induced by expression of viral proteins was not inhibited by BFA, but they were
functionally deficient. GBF1, a guanine nucleotide exchange factor for the small cellular GTPases, Arf, is responsible for the
sensitivity of virus infection to BFA, and is required for virus replication. Knockdown of GBF1 expression inhibited virus
replication, which was rescued by catalytically active protein with an intact N-terminal sequence. We identified a mutation
in GBF1 that allows growth of poliovirus in the presence of BFA. Interaction between GBF1 and viral protein 3A determined
the outcome of infection in the presence of BFA.
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Introduction
All known positive strand RNA viruses replicate their genomes
in association with remodeled cellular membranes. Assembly of
replication complexes on membranes is believed to have several
advantages. Membranes provide a scaffold that increases the local
concentration of proteins involved in replication and facilitates the
proper topological orientation of replication complex components.
The association with membranes protects replicating RNA from
cellular nucleases, and may also prevent induction of cellular
innate immune responses by confining dsRNA or other signaling
intermediates [1].
Poliovirus is a member of the Picornaviridae family, which consists
of small, non-enveloped positive strand RNA viruses that include
numerous human and veterinary pathogens, such as polio,
rhinovirus (common cold virus), hepatitis A virus, and foot and
mouth disease virus. The poliovirus genome is a single RNA
molecule of about 7500 nt in length which is directly translated in
an infected cell into a single polyprotein that undergoes immediate
processing in cis and in trans by three virus-encoded proteases into a
cascade of intermediates and mature polypeptides. Non-structural
proteins, necessary for RNA replication, are encoded in the P2-P3
region of the genome, while coding sequences for structural
proteins, necessary for packaging of progeny RNA but dispensable
for replication, are located in the P1 region (Fig. 1A). Infection of
cells with poliovirus results in rapid and massive reorganization of
virtually all intracellular membranes except for mitochondria, into
clusters of tightly-associated vesicles of heterogeneous size which
harbor viral replication complexes on their surfaces [2,3,4]. These
replication complexes have been shown to be associated with all of
the non-structural viral proteins from the P2 and P3 coding region
[5,6]. Such massive rearrangements in cellular membrane
organization likely require major rewiring of normal membrane
metabolism, but the molecular mechanisms underlying induction,
formation and functioning of poliovirus membranous replication
complexes remain largely unknown. It has been shown that at the
early stages of poliovirus infection non-structural virus protein 2B
co-localizes with COPII-coated vesicles, budding from ER exit
sites [7]. These data together with the observations that poliovirus-
induced vesicles are often found in electron micrographs close to
the remnants of ER [8] suggest that the COPII-dependent
mechanism of vesicle formation may contribute to the develop-
ment of viral replication complexes. However, Shlegel et al. have
identified markers not only from the ER, but also from Golgi and
lysosomes, present on polio-induced vesicles. It was proposed that
autophagy-like processes may be involved in membrane remod-
eling in polio infected cells, which would also explain the large
proportion of double membrane vesicles observed by electron
microscopy of infected cells [9].
Another important clue towards possible cellular pathways
involved in formation of polio replication complexes comes from
the sensitivity of poliovirus infection to brefeldin A (BFA) [10,11].
Interestingly, neither formation of COPII-coated vesicles nor
autophagy are sensitive to BFA [12,13,14], suggesting that these
two processes do not fully account for all cellular pathways
exploited by poliovirus for its replication. BFA is a fungal
metabolite, specifically targeting the activation of small cellular
GTPases, Arfs, which are key regulators of the cellular secretory
pathway. The inactive, cytoplasmic GDP-bound form of Arf, upon
nucleotide exchange to GTP, undergoes conformational changes
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‘‘activated’’; it initiates formation of secretory vesicles and
regulates cytoskeleton functions and lipid metabolism [15].
Conversion of Arf-GDP into Arf-GTP requires the activity of
guanine nucleotide exchange factors (GEFs). In human cells BFA
inhibits the function of three GEFs – GBF1, BIG1 and BIG2 – by
stabilizing transient complexes formed between the GEF and Arf-
GDP. The specificity of BFA action on these GEFs is provided by
the sequence of their Sec7 domains, directly involved in Arf
activation [16].
We have shown previously that Arf-GTP accumulates on
membranes in poliovirus- infected cells. Surprisingly, in an in vitro
reaction, expression of two distinct viral proteins – 3A, a small
membrane-binding protein, and 3CD, a soluble protein with
protease activity – was sufficient to induce Arf translocation to
membranes. We demonstrated that these two proteins specifically
engage different cellular GEFs: 3A induces translocation of GBF1
to membranes while 3CD results in association with membranes of
BIG1 and BIG2 [17,18,19]. Thus, all three mammalian BFA-
sensitive GEFs could be involved in poliovirus replication. Wessels
et al. have demonstrated that direct interaction between GBF1
and 3A from poliovirus or coxsackie virus B3, a close relative of
poliovirus, is responsible for association of GBF1 with membranes
in 3A-expressing cells. When 3A was expressed individually,
binding of 3A to GBF1 resulted in inhibition of the Arf-activating
function of GBF1 [20,21]. This mechanism was proposed to
explain an established phenomenon of inhibition of cellular
protein secretion in polio- and coxsackievirus-infected cells, which
had been shown previously to be caused by 3A expression
[22,23,24]. In this paper we show that in the context of normal
virus replication, functional GBF1 is required for successful virus
propagation, and GBF1-3A interactions determine the outcome of
infection in the presence of BFA. Surprisingly, the BFA-sensitive
step in poliovirus replication was not the morphological remod-
eling of cellular membranes, but the functioning of replication
complexes, suggesting strong dependence of poliovirus RNA
replication on components of the host membrane traffic
machinery.
Results
Sensitivity of poliovirus to BFA depends on the host cell
To determine whether host cell factors contribute to BFA
sensitivity of poliovirus replication, we took advantage of an
available BFA-resistant cell line, BER-40, which was isolated from
parental Vero cells after mutagenesis and subsequent passaging in
the presence of BFA [25]. Vero cells are routinely used in large-
scale viral vaccine production, and they support robust replication
of poliovirus. Figure 1B shows that while replication of poliovirus
in Vero cells was severely inhibited by BFA, the BFA-resistant
derivative of Vero cells, BER-40, was able to support replication of
the virus in the presence of the inhibitor. These results
demonstrate that some cellular BFA-sensitive process is required
for successful propagation of poliovirus in Vero cells.
Mutation in GBF1 is responsible for BFA resistance of
BER-40 cells
To identify the BFA-sensitive host factor involved in poliovirus
replication, we decided to investigate the mechanism of resistance
of BER40 cells to the inhibitor. Previous attempts to identify the
determinants of BFA resistance in BER40 cells were unsuccessful
[25,26,27]. We examined the gene sequences coding for all three
high molecular weight Arf GEFs – GBF1, BIG1 and BIG2 – that
are known to be targets of BFA, to determine whether mutations
were present in BER-40 cells compared with the parental Vero cell
line. Formation of a stable complex between BFA, a sensitive
ArfGEF and Arf-GDP is determined by specific amino acids in the
Sec7 domains of the ArfGEFs; the rest of the protein does not
participate in this interaction [28]. We amplified the Sec7 domain
coding sequences of BIG1, BIG2 and GBF1 from mRNA isolated
from Vero and BER-40 cells. Sequence analysis showed that while
BIG1 and BIG2 Sec7 domains were identical in both cell lines,
BER-40 cells contained two species of GBF1 Sec7 sequences
(Fig. 2A). One corresponded to the same sequence found in the
parental Vero cells, while the other coded for a substitution of the
A in GBF1 residue 795 to E (A795E). The two gene sequences
likely arise from genetic heterozygosity in the BER-40 cells rather
than a mixture of two cell populations, since a sensitive population
would be rapidly selected against in the presence of BFA. To
confirm that this mutation was responsible for the BFA-resistant
phenotype of BER40, we introduced it into an expression plasmid
coding for YFP-GBF1 fusion protein, shown previously to be
indistinguishable from the wild type GBF1 in intracellular
localization and functional activities [29]. The mutated plasmid
was used to transfect HeLa cells, a human cell line commonly used
as a laboratory host for poliovirus and known to be highly sensitive
to BFA. Transfection with the mutated plasmid conferred a greatly
increased resistance to BFA, compared with cells transfected with
an empty vector or cells transfected with a plasmid encoding the
wild type GBF1 sequence (Fig. 2B). In addition to increased cell
survival in the presence of BFA, the BFA-resistant form of GBF1
also rescued the functional properties of the cells’ secretory
pathway, which are known to be sensitive to BFA treatment [30].
HeLa cells were co-transfected with pGLUC plasmid, expressing
Gaussia luciferase with a natural secretion signal, and with plasmids
expressing wild type GBF1, A795E BFA resistant mutant GBF1,
or an empty vector. As seen in Fig. 2C, expression of the A795E
GBF1 mutant almost completely restored secretion in the presence
of BFA. Thus, the mutation in the GBF1 Sec7 domain is the major
Author Summary
All positive strand RNA viruses replicate their genomes in
association with membranous structures that are formed
after infection by remodeling pre-existing cellular organ-
elles. The role of membranes and the mechanisms
exploited by viral proteins to orchestrate the formation
and functioning of viral membranous replication complex-
es are largely unknown. Poliovirus replication is severely
suppressed by brefeldin A (BFA), a well-known inhibitor of
the cellular secretory pathway. Three cellular proteins
(GBF1, BIG1 and BIG2) that activate small GTPases called
Arfs, whose activity is necessary for normal functioning of
the secretory pathway, are known targets of BFA. Here we
demonstrate that poliovirus utilizes the GBF1-dependent
Arf activation pathway for its replication. Our data explain
the mechanism of BFA inhibition of poliovirus replication
by demonstrating that viral protein 3A binds and recruits
GBF1 to membranes that support viral RNA synthesis.
Inactivation of GBF1 by BFA prevents Arf activation and
recruitment, and prevents formation of functional replica-
tion complexes. Surprisingly, formation of membranous
structures morphologically similar to viral replication
complexes occurs in the presence of BFA, although these
structures do not function in the synthesis of viral RNA.
Other plus strand RNA viruses are known to exhibit
sensitivity to BFA and our data suggest that hijacking of
the Arf activation pathway may be a common feature
shared by diverse groups of viruses.
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transfer BFA resistance to HeLa cells.
BFA-resistant, catalytically-active GBF1 rescues
replication of poliovirus
The GBF1 mutation in Ber40 cells conferred resistance of cell
growth to BFA, and we predicted that this same mutation also was
responsible for poliovirus growth in Ber-40 cells (see Fig. 1B). We
have previously shown that ectopic expression of GBF1 can
partially rescue poliovirus replication in the presence of BFA in
HeLa cells [31]. To determine whether the growth of poliovirus in
BER-40 cells in the presence of BFA was due to the mutated
GBF1, we compared the replication of a poliovirus replicon in
HeLa cells transfected with plasmids coding for either the wild
type or the A795E form of GBF1. Figure 2D shows that replicon
replication in the presence of BFA occurred with much greater
efficiency in cells expressing GBF1 A795E. Equal amounts of wild
type and mutant GBF1 proteins were synthesized, as measured by
western blot analysis (Fig. 2D, right panel). Thus, the substitution
of A795E found in the GBF1 sequence from BER-40 cells is
responsible for resistance of both cell secretion and viability and
poliovirus replication to BFA. We also tested whether the rescue of
polio replication from BFA inhibition in HeLa cells was dependent
on GBF1’s ability to functionally activate Arf. To this end, we
exploited another GBF1 mutation that encoded a protein with a
single amino acid substitution in the Sec7 domain (E794K), which
was shown previously to be inactive in Arf activation [32]. HeLa
cells were transfected with expression plasmids for wild type GBF1
and for the E794K GBF1 mutant. While a polio replicon was able
to replicate in the presence of BFA in cells expressing active GBF1,
cells expressing the inactive GBF1 mutant were unable to support
polio replication in the presence of the same concentration of
inhibitor (Fig. 3A), demonstrating that the ability of GBF1 to
activate Arf is required for polio replication.
Depletion of GBF1 reduces polio replication
As a second approach to evaluate the requirement of GBF1 for
poliovirus replication even in cells not treated with BFA, we
depleted GBF1 levels in untreated HeLa cells with siRNA. The
depletion of GBF1 was very effective after three days of siRNA
Figure 1. Inhibition of poliovirus growth by BFA depends on the host cell. A. Schematic map of the poliovirus genome. B. Poliovirus was
propagated on Vero or BER-40 cells for 6 h in the presence of 2 mg/ml BFA. Virus yields were measured by plaque assay on HeLa cell monolayers.
Dilutions of the infected cell suspensions are indicated.
doi:10.1371/journal.ppat.1000216.g001
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inhibited compared with cells treated with control siRNA (Fig. 3C).
Upon completion of the replication experiments the cells treated
with GBF1 siRNA showed some signs of cytotoxicity and lysis [33]
which resulted in reduction in the amount of BIG2, another high
molecular GEF, as well as other bands (not shown) on blots of
lysates obtained from GBF1 siRNA-treated cells (Fig. 3B).
However, expression levels of control proteins from plasmids
introduced at the same time as the polio replicon were identical in
control cells and cells treated with GBF1 siRNA (not shown),
confirming the specificity of inhibition of polio replication by
GBF1 knock-down. We also performed the same experiment in
the presence of a broad range caspase inhibitor zVAD-fmk, to
prevent possible depletion of cells transfected with polio replicon
due to apoptosis, known to be triggered when polio replication is
suppressed [34]. Treatment of cells with zVAD-fmk did not
change the reduction of polio replication in cells with knocked
down GBF1 expression (not shown). Together, these results show
that polio RNA replication strongly depends on the activity of
GBF1.
Expression of constitutively activated Arf1 Q71L mutant
does not rescue polio replication from GBF1 loss of
function
Since Arf activation by GBF1 appeared to be essential for polio
replication, we tested whether expression of Arf1 Q71L, a mutant
Arf1 protein that manifests increased affinity for GTP and
therefore does not require GEF-mediated nucleotide exchange
to be activated [35], can rescue polio replication under conditions
Figure 2. GBF1 sequence determines BFA resistance of cells and virus. A. Sequencing chromatograms of GBF1 Sec7 domain from Vero and
BER-40 cells. Results from analyses with three different primers are shown. B. GBF1 A795E mutant confers BFA resistance to HeLa cells. Cells were
transfected with either a control vector, vector expressing wild type YFP-GBF1 fusion or vector expressing YFP-GBF1 A795E mutant fusion, and
subsequent cell growth in the presence of BFA was measured by a luminescent cell viability assay. C. Expression of GBF1 A795E mutant rescues
protein secretion in the presence of BFA. Cells were co-transfected with pCMV-Gluc vector expressing secreted Gaussia luciferase and with either
control plasmid or with vectors expressing wild type GBF1-YFP or GBF1 A795E-YFP fusions. The amount of secreted protein observed in each sample
without BFA was defined as 100%. D. GBF1 A795E mutant rescues replication of poliovirus in the presence of BFA. A polio Renilla luciferase replicon
was introduced in HeLa cells previously transfected with vectors expressing wt YFP-GBF1 fusion, YFP-GBF1 A795E mutant or with an empty vector.
BFA was added where indicated at 1 mg/ml concentration at the time of replicon transfection, and polio RNA replication was measured by luciferase
assay. Expression of the GBF1 proteins was measured by Western blot; calnexin staining was used as a loading control (panel D, right).
doi:10.1371/journal.ppat.1000216.g002
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this Arf mutant did not support polio replicon replication in the
presence of BFA, nor did expression of this mutant restore polio
replication in cells treated with anti-GBF1 siRNA (not shown).
These data are consistent with previous analyses of the Arf Q71L
protein. Expression of this mutant prevented BFA-induced Golgi
Figure 3. Requirement of active GBF1 for poliovirus replication in the presence of BFA. A. HeLa cells were transfected with a plasmid
expressing active YFP-GBF1 fusion, inactive YFP-GBF1 E794K fusion or control vector one day prior to transfection with a polio replicon containing the
Renilla luciferase gene, and incubated in the presence of 1 mg/ml of BFA where indicated. Luciferase activity was assayed as a measure of polio RNA
replication. The Western blot on the right shows expression of GBF1 derivatives. Actin staining served as a loading control. B. HeLa cells were treated
with either GBF1 or control non-specific siRNA for 3 days prior to transfection with the polio Renilla replicon. The Western blot shows the level of
knock down of GBF1 protein. The same membrane was stripped and probed again with anti-BIG2 antibodies as a loading control. C. HeLa cells were
transfected with either a control vector or plasmid pArf1 Q71L-CFP, expressing a constitutively activated form of Arf1-CFP fusion. The next day the
cells were transfected with a polio replicon containing the Renilla luciferase gene, and incubated in the presence of 2 mg/ml of BFA where indicated.
Luciferase activity was assayed as a measure of polio RNA replication. The Western blot on the right shows expression of Arf1 Q71L-CFP fusion. Actin
staining serves as a loading control.
doi:10.1371/journal.ppat.1000216.g003
GBF1 Is Required for Poliovirus Replication
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because this Arf is unable to cycle, COPI became irreversibly
locked on membranes and was not functional [35,36,37,38]. Thus,
viral RNA replication depends on the precise temporal and spatial
regulation of GBF1-dependent Arf activation and cycling that is
characteristic of this group of G proteins. The possibility that there
is an Arf-independent GBF1 function that is required for virus
replication also cannot be excluded.
Expression of polio 3A protein stimulates GBF1-
dependent Arf activation in vitro
To confirm that 3A-induced recruitment of GBF1 to mem-
branes results in Arf activation, we utilized an in vitro system that
has been extensively exploited to reveal the biochemical
machinery of poliovirus RNA replication [39,40,41,42,43]. RNA
coding for poliovirus 3A was translated in HeLa cell extracts, and
membranes were collected by centrifugation and analyzed by
immunoblot to asses the proteins that were membrane-associated.
As we showed previously [31] synthesis of 3A resulted in increased
association of GBF1 with membranes (Fig. 4, GBF1 row; compare
lanes 1 and 3). Interestingly, a significant accumulation of GBF1
on membranes was also observed in samples treated with BFA,
independent of the synthesis of polio 3A protein (Fig. 4, GBF1
row; compare lanes 1, 2 and 4). However, only 3A synthesis
resulted in increased amounts of Arf on the membranes. As
expected, this Arf was activated, as evidenced by the recruitment
of components of the COPI coatomer complex, a downstream
effector of Arf activated through the GBF1-dependent pathway
[44]. No Arf or COPI accumulation was observed in samples
treated with BFA, regardless of the GBF1 association with
membranes (Fig. 4 compare lanes 1, 2 and 4). These results
clearly distinguish between the functional and abortive recruit-
ment of GBF1 to membranes induced by 3A vs. BFA.
Recruitment of GBF1 to membranes induced by poliovirus
protein 3A leads to a productive cascade of Arf activation and
COPI coatomer recruitment, consistent with our previous report
[31] that increased levels of Arf-GTP steadily accumulate on
membranes with time during poliovirus infection of HeLa cells.
Figure 4. Synthesis of poliovirus protein 3A stimulates GBF1-dependent Arf activation in vitro. RNA coding for poliovirus 3A was
translated in HeLa cell S10 extracts. The samples contained 80 mg/ml BFA where indicated (or the corresponding amount of solvent DMSO in other
samples). The membranes were collected by centrifugation and assessed by western blot with anti-GBF1, anti-Arf and anti-COPI antibodies.
Translation efficiency was monitored by labeling an aliquot of the translation reaction with
35S methionine (lower panel).
doi:10.1371/journal.ppat.1000216.g004
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determines sensitivity of virus replication to BFA
The 3A protein of coxsackievirus B3 (CVB3) was shown
previously to interact with the N-terminus of GBF1 [21]. CVB3
and poliovirus are closely related enteroviruses, so we speculated
that a similar interaction between poliovirus 3A protein and GBF1
might account for the observed requirement for GBF1 in
poliovirus replication. First we examined the BFA sensitivity of a
wild type poliovirus replicon and a mutant replicon containing an
insertion of a Ser residue at position 15 in the 3A sequence. This
mutant, called 3A-2, was shown previously to be defective in
inhibiting the cellular secretory pathway [22,45]. Wessels et al.
showed that when the mutation corresponding to polio 3A-2 was
introduced into CVB3, the resulting 3A protein manifested a
severely decreased binding to GBF1 [46]. Replication of the 3A-2
replicon showed an approximately one-hour delay compared with
wild type before the rapid phase of viral RNA synthesis begins.
Although the final replication level was only slightly less than wild
type in the absence of inhibitor (see insets, Fig. 5A and B),
replication of the mutant was completely abrogated even at the
lowest concentration of the inhibitor tested. The wild type replicon
displayed intermediate levels of sensitivity at low BFA concentra-
tions (Fig. 5A).
We also tested the level of rescue of replication of the 3A-2
mutant replicon in the presence of BFA by ectopic expression of
GBF1. In this experiment we used our BFA-resistant A795E
GBF1, to obtain the maximum level of rescue. As shown in Fig. 5B,
the response of the 3A-2 mutant was significantly lower than that
of the wild type replicon. Finally, we showed that GBF1
knockdown had a significantly greater inhibitory effect on the
replication of the 3A-2 polio replicon than on the wild-type
replicon. In this experiment we treated cells with GBF1 siRNA for
a shorter period – 2 days instead of 3- to minimize cytotoxicity of
the siRNA and therefore to be able to detect weaker possible
replication of the 3A-2 replicon. Under these conditions the
reduction in replication of the wild type replicon was clearly visible
but, as expected, was less than 90% observed in the cells treated
with GBF1 siRNA for 3 days, while replication of the 3A-2
replicon was inhibited to a much greater extent (Fig. 5C).
We have shown previously that synthesis of polio 3A protein in
HeLa cell extracts results in accumulation of GBF1 on membranes
([31] and Fig. 4). To see if the pattern of BFA inhibition of
replication of polio variants correlated with the ability of the
corresponding 3A proteins to engage GBF1 on the membranes, we
translated RNAs coding for wild type 3A and 3A-2 mutant in
HeLa cell extracts, collected membranes with their associated
proteins by centrifugation and assessed the amount of GBF1 by
Western blot. Figure 5D shows that the amount of GBF1 bound to
membranes after translation of 3A-2 mutant RNA was signifi-
cantly less than after translation of wild type 3A RNA, correlating
with the strong sensitivity of the 3A-2 replicon to BFA. Although
the amount of GBF1 found associated with membranes upon
translation of 3A-2 coding RNA varied in different batches of
HeLa cell extracts, usually synthesis of 3A-2 mutant protein did
induce some association of GBF1 with membranes compared with
the background levels. Taken together, the data show that the 3A-
2 mutant is more sensitive to BFA, more sensitive to depletion of
GBF1 by siRNA kockdown, and is harder to rescue from BFA
inhibition by providing ectopic GBF1. These properties are all
consistent with low-affinity binding between 3A-2 and its target
GBF1, whose activity is required for virus growth.
This analysis does not discriminate between a direct interaction
of 3A with GBF1 and indirect activation of GBF1 translocation to
membranes by a pathway triggered by 3A. To compare the
strength of direct interaction between the two proteins we
performed yeast two-hybrid studies with the soluble interacting
domains of the wild type and 3A-2 mutant 3A polypeptides (amino
acid residues 1–60) and GBF1. Our results (not shown) confirmed
previous studies performed in a mammalian two-hybrid system,
showing a strong interaction between wild type poliovirus 3A and
GBF1 and the severe inhibition of such interaction for the 3A-2
mutation in the corresponding Coxsackie virus protein [20,46].
Thus our data show that the sensitivity of poliovirus replication to
inhibition by BFA correlates inversely with the strength of
interaction of viral protein 3A and GBF1.
The domain attributed with binding to viral protein 3A was
shown to reside in the N-terminal region of GBF1. A deletion of 37
N-terminal amino acids of GBF1 resulted in the loss of interaction
with 3A protein from CVB3, as detected by co-immunoprecipi-
tation experiments [46]. We tested this D37 mutation in GBF1 for
its ability to rescue polio replication in the presence of BFA. To
ensure as great a potential rescue level as possible, we combined
the D37 mutation with the BFA-resistance mutation A795E,
identified in GBF1 from BER-40 cells. Although expression of the
YFP fusions of the full length A795E GBF1 was very efficient in
rescuing replication of polio replicon RNA in the presence of the
inhibitor, the truncated variant of GBF1 was completely ineffective
(Fig. 6A). We also tested whether this truncated variant of GBF1
combined with the A795E mutation could confer BFA resistance
to HeLa cells. The survival experiments did not show any
protection of cells expressing this GBF1 variant from BFA as
opposed to cells expressing full length A795E GBF1 (not shown).
Therefore the N-terminal region of GBF1 provides some
important function(s) required for BFA resistance for both virus
replication and cell survival.
We monitored the distribution of Venus fusions of wild type
GBF1 and D37 mutant GBF1 in cells infected with poliovirus. The
localization of both proteins in mock-infected cells was virtually
identical: they were associated with cytoplasmic ER-like structures
with some slight concentration in the perinuclear area (Fig. 6B,
panels D and H). In infected cells the two proteins behaved very
differently. As we reported previously, wild type GBF1 relocalized
to sites of poliovirus replication, visualized by staining of 3A
protein (Fig. 6B panels A–C) [31]; the D37 mutant GBF1 showed
no apparent association with membrane structures, and displayed
the diffuse fluorescence typical of a soluble protein (Fig. 6B panels
E–G). A characteristic feature of infected cells expressing the
truncated GBF1 mutant was the positive staining of the nucleus,
which was always spared in cells expressing wild type GBF1
(Fig. 6B panels A, E) and in mock-infected cells expressing either
protein (Fig. 6B panels D, H). The difference between localization
of wt GBF1 and the D37 mutant in infected cells is likely due to the
inability of the deletion mutant to be tethered to membranes
because of loss of a domain responsible for interaction with protein
binding partners, including polio protein 3A.
BFA inhibits function of poliovirus replication complexes
but not virus-induced remodeling of cellular membranes
GBF1-induced activation of Arf is required for formation of
COPI-coated vesicles in the traffic between ER and cis-Golgi of
the cellular secretory pathway [44]. The association of activated
Arf with membranes also recruits numerous effector proteins and
changes membrane properties due to activation of lipid-modifying
enzymes such as phospholipase D [15,47]. Although polio RNA
replication clearly requires active GBF1, the Arf-GTP generated
by this GEF may participate in two not necessarily mutually
exclusive processes: the remodeling of cellular membranes into
characteristic polio-induced vesicles, and/or the generation of a
GBF1 Is Required for Poliovirus Replication
PLoS Pathogens | www.plospathogens.org 7 November 2008 | Volume 4 | Issue 11 | e1000216Figure 5. Mutation in poliovirus 3A protein increases viral sensitivity to BFA and decreases recruitment of GBF1 to membranes. A.
HeLa cells were transfected with either wild type or 3A-2 mutant polio Renilla replicons and incubated in the presence of the indicated amounts of
BFA. Luciferase was assayed as a measure of polio RNA replication. The inset shows a direct comparison of the wild type and 3A-2 replicons in the
absence of BFA. B. HeLa cells were transfected with a plasmid expressing YFP-GBF1 A795E, a BFA-resistant mutant of GBF1, or a control vector. The
next day the cells were transfected with either wild type or 3A-2 mutant polio Renilla replicon RNA and incubated with or without 1 mg/ml of BFA
while RNA replication was monitored. The inset shows a direct comparison of the wild type and 3A-2 replicons in the cells transfected with an empty
vector in the absence of BFA. C. HeLa cells were treated with either GBF1 or control non-specific siRNA for 2 days prior to transfection with the polio
Renilla wild type or 3A-2 mutant replicons. Luciferase was assayed as a measure of polio RNA replication. D. RNA coding for either wild type 3A or 3A-
2 mutant was translated in HeLa cell S10 extracts. The membranes were collected by centrifugation and assessed by western blot with anti-GBF1
antibodies. The same membrane was stripped and probed again with anti-calnexin antibodies as a loading control. Translation efficiency was
monitored by labeling an aliquot of the translation reaction with
35S methionine (lower panel).
doi:10.1371/journal.ppat.1000216.g005
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Since virus replication is inhibited by drugs that prevent Arf
activation, such as BFA, we attempted to determine whether BFA
affected either of these two potential inputs of Arf into poliovirus
replication. To this end, we utilized a non-replicating poliovirus
RNA where the cognate regulatory sequences in the 59 non-
translated region were substituted with an IRES from encepha-
lomyocarditis virus (EMCV) to express polioviral proteins. This
Figure 6. The N-terminal region of GBF1 is important for rescue of polio replication from BFA inhibition and for localization to sites
of viral RNA synthesis. A. HeLa cells were transfected with vectors expressing YFP-GBF1 fusions with BFA-resistance mutation A795E with either
the wild type N-terminus or with a deletion of 37 N-terminal amino-acids (D37). The next day the cells were transfected with polio Renilla replicon
RNA and incubated in the presence or absence of 1 mg/ml BFA while monitoring viral RNA synthesis. B. HeLa cells were transfected with plasmids
expressing Venus-GBF1 fusions with either wild type N-terminus (panels A–D) or with a deletion of 37 N-terminal amino-acids (D37) (panels E–H). The
next day cells were infected with poliovirus at a multiplicity of 10 PFU/cells (panels A–C and E–G) or mock-infected (panels D and H), incubated for
4 h, fixed and processed for immunofluorescent staining with anti-polio 3A antibodies (red). Nuclear chromatin is stained with Hoechst 33342.
doi:10.1371/journal.ppat.1000216.g006
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by T7 RNA polymerase produced from a recombinant vaccinia
virus. In this case accumulation of poliovirus-specific RNA is not
dependent on replication, and the synthesis of polio proteins is not
affected by the presence of brefeldin A. This construct was used
previously to show that synthesis of poliovirus proteins, not RNA
replication, is sufficient to form the vesicular structures morpho-
logically indistinguishable from those found in poliovirus-infected
cells [48]. When the transfected cells were examined by electron
microscopy, specific polio-induced vesicles were observed to have
formed, both in the presence and the absence of BFA, thus arguing
that Arf activation is not necessary for the morphological
development of these structures (Fig. 7A). To monitor the
distribution of Arf in cells expressing poliovirus proteins in the
presence of BFA we performed a similar experiment in cells
expressing an Arf1-EGFP fusion protein. As seen in Fig. 7B,
staining of poliovirus protein 3A revealed that regardless of the
presence of BFA, the viral protein was localized in the
characteristic perinuclear ring of vesicle-like structures (compare
panels B and F), while Arf translocated to this region only in the
absence of the inhibitor (compare A and E; C and G). As expected,
Arf translocation to the virus-induced vesicular structures did
occur in the presence of BFA in cells transfected to express the
BFA-resistant A795E GBF1 mutant (not shown).
The results of this experiment show that in the presence of
BFA, when GBF1-dependent Arf activation could not occur, it
is possible to form polio-induced membranous structures
morphologically indistinguishable from those developed in the
absence of the inhibitor. To determine whether these structures
were capable of supporting polio RNA replication, we allowed
them to form in the presence of absence of BFA with a
replication-competent RNA, and then measured their subse-
quent ability to synthesize RNA. Viral proteins were synthesized
from polio RNAs generated by T7 RNA polymerase supplied
by recombinant vaccinia virus. To ensure that equal amounts of
proteins were produced during the stage of membrane
remodeling with and without BFA, both samples were incubated
in the presence of 2 mM guanidine-HCl, a specific and
reversible inhibitor of polio RNA replication that prevented
amplification of viral RNA template. The cells were incubated
for 4.5 hours, the time that we found in the previously-
described electron microscopy studies to be sufficient for
vesicular structures to form. The presence of guanidine-HCl
during this time blocked RNA replication from starting even if
competent replication complexes had formed. After 4.5 hours,
the guanidine-HCl was removed to allow viral RNA synthesis to
proceed from the pre-formed protein-membrane complexes.
Figure 8A shows that polio RNA replication was detected only
when the initial incubation was performed without BFA,
showing that the vesicular structures associated with viral
replication proteins formed when Arf activation was inhibited
were unable to support viral RNA synthesis despite their similar
morphological appearance. To confirm that the observed
increase in Renilla signal from the cells whose replication
complexes were formed in the absence of BFA was not simply
due to healthier cells incubated without BFA, we performed a
similar experiment with a plasmid coding for a replication-
defective polio RNA containing a deletion in the polymerase
gene. In this case no differences were seen between the samples
regardless of their BFA treatment (Fig. 8B). These data
demonstrate that the BFA-sensitive (and Arf activation-depen-
dent) step in polio replication is not the remodeling of host
membrane structures, but the ability of those structures to
function in viral RNA replication.
Discussion
Viruses ultimately must depend on cellular structures and
factors for their replication. Often host proteins in infected cells are
diverted to perform their normal function(s) in a new microenvi-
ronment or with modified specificity. In this paper we show that
replication of poliovirus strongly depends on the activity of a
cellular protein, GBF1. GBF1 activates the small cellular GTPase,
Arf1, by exchanging Arf-bound GDP for GTP to regenerate the
active form of Arf. In uninfected cells, GBF1 is required for
specific steps during the transfer of proteins and membranes
through the secretory pathway, from ER through the Golgi to
plasma membrane or endosomes. Activation of Arf by GBF1
occurs during formation of COPI-coated vesicles from the ER-
Golgi intermediate compartment (ERGIC). This activity of GBF1
is inhibited by BFA which binds and stabilizes the Arf1-GDP-
GBF1 intermediate complex and thus prevents GBF1 from
performing multiple rounds of Arf activation [28,29]. Replication
of poliovirus is also sensitive to this inhibitor [10,11]. We
demonstrate that GBF1 can rescue poliovirus infection from
inhibition by BFA, and that reduced interaction between GBF1
and viral protein 3A increases the sensitivity of poliovirus infection
to BFA. Inhibition of polio replication by BFA is specific for the
particular host cell, and this specificity is determined by the
sequence of the catalytic Sec7 domain of GBF1 in the cell. We
identified a new mutation in GBF1, A795E, that renders the factor
resistant to BFA. Expression of this BFA-resistant GBF1 conferred
BFA resistance to HeLa cells and allowed efficient rescue of
poliovirus replication in the presence of BFA. This mutation
generates a single amino acid substitution at a residue that is very
close to the BFA binding site identified on the crystal structure of
the complex between the GEF Sec7 domain, BFA and Arf-GDP
[49,50]. The crystal structure of a modified Arno Sec7 domain
complexed with Arf1 and BFA shows that the corresponding
residue (A157) participates in direct van der Waals interaction with
BFA. Interestingly, another amino acid in the Sec7 domain of
GBF1, M832, whose substitution to L also makes GBF1 resistant
to BFA, is located very close to A795 in the crystal structure and
also participates in van der Waals contact with BFA [29,49].
Previous work from this laboratory demonstrated that two other
high molecular weight GEFs that activate Arf, BIG1/BIG2, are
recruited to polio replication complex membranes, both in vitro
and in infected cells [31]. Recruitment of BIG1/BIG2 was
mediated by viral protein 3CD, independent of 3A’s recruitment
of GBF1. Since the activities of these two GEFs are also sensitive to
BFA, the data described in this report suggest that BIG1/BIG2
also are not involved in the morphological development of
replication vesicles. It is not yet clear whether or what role these
GEFs play in this complex process [17], since any or all of them
might perform BFA-insensitive functions that could affect
membrane remodeling or other aspects of polio replication.
Wessels et al. have performed elegant studies on the fate and
consequences of expressing just the 3A protein from polio or
Coxsackie virus B3 in mammalian cells. They found loss of COPI
coatomer complex on membranes and reduction of activated Arf
[21]. They also showed that 3A interacts directly with GBF1, and
concluded that this interaction resulted in inhibition of the Arf-
activating property of GBF1 when 3A was expressed by itself in
mammalian cells. The single amino acid insertion in the 3A-2
mutant caused the viral protein to lose detectable binding to GBF1
and therefore did not inhibit GBF1’s GEF activity [20,46]. It was
proposed that this 3A-induced inhibition of GBF1 GEF activity
was responsible for shutting down the secretory pathway in
infected cells. In the course of virus infection, 3A protein is
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PLoS Pathogens | www.plospathogens.org 10 November 2008 | Volume 4 | Issue 11 | e1000216Figure 7. Polio-induced vesicles form in the presence of BFA, but fail to induce Arf1 relocalization. A. Polio non-structural proteins were
expressed from non-replicating RNA. The cells were incubated in the presence or absence of 2 mg/ml of BFA. An equivalent amount of DMSO solvent
was added to the incubation medium in the sample without BFA. After 4.5 h incubation, cells were fixed and processed for electron microscopy. B.
Poliovirus non-structural proteins were expressed from non-replicating RNA in HeLa cells expressing Arf1-EGFP fusion. The cells were incubated in the
presence of 2 mg/ml of BFA where indicated (panels E–H). An equivalent amount of DMSO solvent was added to the incubation medium in samples
without BFA (panels A–D). To observe the localization of Arf1-EGFP fusion protein in cells without expression of polio proteins, an empty plasmid was
substituted for the polio cDNA-bearing plasmid (panels D and H).
doi:10.1371/journal.ppat.1000216.g007
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in interactions with other viral products that may significantly
modify the outcome of its interactions with cellular proteins
[51,52]. Our previous data showed that the amount of Arf-GTP
steadily increased during the course of infection [31]; thus at least
overall GEF activity in infected cells is not inhibited. Moreover
Gazina et al. demonstrated that components of COPI coats, whose
association with membranes is directly dependent on GBF1-
induced Arf activation, are associated with replication complexes
of echovirus 11, a related picornavirus that is sensitive to BFA
[53]. A genetic screen of Drosophila cells identified the COPI
coatomer as a host factor essential for growth of another
picornavirus-like virus, Drosophila C virus [54]. These data do
not support the notion that GBF1 activity is inhibited in infected
cells. Our data presented here directly show that GBF1 is
necessary for poliovirus replication and that only expression of
catalytically active GBF1 can rescue poliovirus replication in the
presence of BFA. Moreover we showed that synthesis of 3A results
in stimulation of GBF1-dependent activation of Arf in vitro. These
latter experiments are the most difficult to reconcile with the
results from the van Kuppeveld laboratory [21] since they
demonstrate stimulation rather than inhibition of Arf activation
even in the absence of other viral proteins. Collaborative studies in
both laboratories are currently in progress to attempt to
understand these apparently conflicting results. Our data also
suggest that although the 3A-2 mutant may manifest a much
weaker interaction with GBF1, it still retains some residual ability
to induce association of this protein with membranes. We propose
that interaction of 3A with GBF1 diverts its activity from its
normal function in the secretory pathway to sites of polio
replication where it functions in poliovirus (and likely other
BFA-sensitive picornaviruses) replication. This diversion to viral
replication complexes would likely result in inhibition of cellular
secretion. Inhibition of cellular secretion leads to reduced
presentation of antigens on the surface of infected cells as well as
reduced release of cytokines [22,55]. Thus, effective subversion of
a cellular pathway may provide a double benefit for the virus by
sustaining genome replication in the cell as well as inhibiting a
pathway important for the organism’s defense against infection.
Inhibition of the cellular secretory pathway was suggested to
provide an advantage for replication of the virus in an animal host,
but was believed to be dispensable for replication in cells culture.
Although the 3A-2 mutation was found to strongly reduce
poliovirus’s ability to inhibit cellular secretion [23], it was reported
not to interfere significantly with propagation of the virus in cell
culture. On the other hand, when the corresponding mutation was
introduced into CVB3, the mutant was less pathogenic in mice
[21]. The mechanism of the apparent attenuation remains to be
elucidated.
What roles do GBF1-dependent reactions play in poliovirus
replication? GBF1 normally participates in the formation of
COPI-coated vesicles on ERGIC structures, and poliovirus
replication complexes form on membranous structures that
resemble clusters of heterogeneously sized vesicles. Thus, GBF1
may possibly be involved in remodeling host membranes into
those structures. In poliovirus-infected cells, however, develop-
ment of infection very rapidly results in complete reorganization of
cellular organelles into specific membranous vesicles, so that ER,
ERGIC and other structures are no longer detectable [2],
although some early secretory pathway steps could still be
observed in infected cells [56]. Therefore infected cells very
rapidly lose the normal morphological substrate for formation of
COPI-like vesicles. Supporting this idea is our observation that the
D37 mutant of GBF1 is distributed like a soluble protein in
infected cells while it is indistinguishable from the wt GBF1 in
mock-infected cells. Apparently GBF1 in polio-infected cells is no
longer retained on membranes through its normal interactions,
such as binding to Rab1b and/or p115 [57,58], but wt protein is
tethered on remodeled membrane structures through binding to
polio protein 3A, while the D37 GBF1 mutant is unable to interact
with 3A and therefore behaves like a soluble protein. Poliovirus
infection is known to induce rapid degradation of nuclear pores
and consequent leakiness of the nuclear envelope that allow even
high molecular weight soluble proteins to freely penetrate the
nuclear envelope in both directions [59,60]. Another set of data
also suggests that the BFA-sensitive (and therefore the GBF1-
dependent) step in poliovirus replication is not remodeling of
membranes but rather proper functioning of the replication
Figure 8. Vesicles formed in the presence of BFA do not support viral RNA replication. A. Polio Renilla replicon RNA was synthesized in
cells in the presence of 2 mM guanidine-HCl and 2 mg/ml BFA as indicated. These conditions allowed for RNA translation and formation of vesicles,
but prevented RNA synthesis. After 4.5 h the medium was changed to remove guanidine-HCl and allow RNA synthesis, and Renilla luciferase activity
was monitored as a measure of viral RNA replication. BFA and guanidine were present at both steps in the control sample. B. The same experiment
was performed with a replicon containing a deletion in the polymerase gene.
doi:10.1371/journal.ppat.1000216.g008
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every stage of the replication cycle ([11]; our unpublished
observations), which would be difficult to reconcile with the
requirement of such activity only for the morphogenesis of
replication structures. Our experiments presented here directly
show that BFA does not preclude formation of characteristic
vesicle-like structures. The similar appearance by low-power
electron microscopy of the membrane structures formed by viral
proteins in the presence and absence of BFA was surprising;
however, the apparent similarity does not imply that these
structures are biochemically and functionally similar, as evidenced
by the differences in Arf1 localization and very likely numerous
other markers including the effectors normally recruited by Arf.
Those structures are unable to support polio RNA replication
when the inhibitor is removed. Association of activated Arf with
membranes is known to induce binding of many effector proteins
and coat complexes and to activate membrane-modifying enzymes
[15,47]. It is likely that in the polio-induced vesicles, Arf’s role
could be to bring to the membranes other host proteins that
participate in replication of the viral genome or in regulating the
lipid composition of these structures to make them suitable for
assembly of functional replication complexes. Interestingly,
expression of the Arf1Q71L mutant that has increased affinity
for GTP and therefore is always in an ‘‘activated state’’ was not
able to restore polio replication from either inhibition of GBF1
activity by BFA or from knock-down of GBF1 expression by
siRNA. This result may indicate that GBF1 performs some other
function in polio replication, unrelated to Arf activation, but the
most likely explanation of this inability of the Arf1 Q71L mutant
to rescue polio replication is that the replication process requires
Arf that can perform normal cycling between its GTP- and GDP-
bound form, while Arf1 Q71L is constantly activated and bound to
membranes [35,36,37,38].
All positive strand RNA viruses remodel host membranes into
novel structures where replication complexes are assembled, and
RNA replication of at least some of them was shown to be sensitive
to BFA [53,61]. It is likely that BFA-sensitive Arf activation is the
cellular pathway exploited by diverse groups of RNA viruses.
Materials and Methods
Cells
HeLa cells were maintained in Dulbecco’s Minimum Essential
Medium, high glucose modification, supplemented with 1 mM
sodium pyruvate and 10% heat-inactivated fetal bovine serum.
BFA-resistant BER-40 cells and their parental Vero cell line were
kindly provided by T. Oda, University of Nagasaki, Japan. They
were grown in Eagle’s Minimum Essential Medium supplemented
with 10% heat-inactivated fetal bovine serum.
Plasmids
Plasmids pXpA-3A and pXpA-3A-2, coding for poliovirus wild
type 3A and 3A-2 mutant, respectively, have been described [19].
The pXpA-RenR plasmid, encoding a poliovirus replicon with the
Renilla luciferase gene substituting for the capsid coding sequence
was previously described [31]. Plasmid pXpA-RenR 3A-2 was
obtained by point mutagenesis, and the mutagenized fragment was
verified by sequencing. Plasmid pTM-PV-2A-39, used for
expression of poliovirus non-structural proteins under translational
control of the EMCV IRES was generously provided by N.
Teterina in our laboratory. Plasmid pXpA-RenR D3D is a
derivative of pXpA-RenR with a deletion of 190 nt in the polio
polymerase sequence. Plasmid pYFP-GBF1, pYFP-GBF1 E794K
and pVenus-GBF1 for expression of GBF1 derivatives have been
previously described [29]; pVenus-GBF1 D37, derived from
pVenus-GBF1, was constructed by T. Niu. Plasmid pArf1-EGFP
for expression of Arf1-EGFP fusion was described elsewhere [36].
Plasmid pArf1Q71L-CFP was a gift from N. Altan-Bonnet
(Rutgers University, New Jersey). Plasmid pCMV-Gluc used for
the secretion rescue experiment was purchased from New England
Biolabs.
Antibodies
Rabbit polyclonal anti-GBF1 antibodies were a gift from N.
Altan-Bonnet, Rutgers University, New Jersey. Anti-BIG2 rabbit
antibodies were generously provided by M. Vaughan, NHLBI,
NIH. Anti-polio 3A mouse monoclonal antibody was a gift from K.
Bienz, University of Basel, Switzerland. Rabbit polyclonal anti-
COP a and c were a gift from F. van Kuppeveld, Radbout
University, the Netherlands. Mouse monoclonal anti-Arf antibodies
recognizing all species of mammalian Arf except Arf4 were from
Affinity Bioreagents. Mouse monoclonal anti-actin antibodies
conjugated with horse radish peroxidase were from Sigma. Mouse
monoclonal anti-GFP antibodies were form Clontech. Secondary
antibody Alexa Fluor 594 conjugates used in immunofluorescence
were from Molecular Probes. Secondary antibody horse radish
peroxidase conjugates used in Western blots were from Amersham.
Poliovirus propagation assay
Vero or BER40 cells grown on 6 cm plates were infected with
poliovirus at multiplicity of 10 PFU/cell and incubated in the
presence of 2 mg/ml of BFA for 6 hours. The cells were subjected
to three freeze-thaw cycles to release intracellular virus, and virus
yield was determined by standard plaque assay on HeLa cell
monolayers.
Sequencing of Sec7 domains of BIG1, BIG2 and GBF1
Poly(A)-containing RNA from Vero and BER-40 cells was isolated
with Oligotex mRNA Mini Kit (Qiagen) according to the manual.
Reverse transcriptase reaction with oligo-dT primer was performed
with MonsterScript 1
st-Strand cDNA Synthesis kit (Epicentre
Biotechnologies). Sec7 –containing fragments were amplified by
PCR using Phusion High Fidelity PCR kit (Finnzymes). Big1 Sec7
PCR primers: GATCGGTCGACACTAGTAAATGATCTATC
(forward) GATCGAAGCTTCTTAAGAAATCCTTCTGG (re-
verse); Big2 Sec7 PCR primers: AGTCAGCATGCATT-
TAAATGCTGCTAAC (forward), GACTGAAGCTTACCGG-
TTCCTATCAG (reverse); GBF1 Sec7 PCR primers: TCA-
GAAAGCTTATGGAGATCATCACTGTGG (forward) CAGA-
GAATTCCTTAAGCAGAGACTTAGTGTC (reverse). Sequenc-
ing primers are available upon request.
Polio replicon assays
Polio replicon RNA was transfected into HeLa cells grown in 96
well white plates with a clear flat bottom (Costar) at 10 ng/well
with Trans-it mRNA transfection reagent (Mirus) according to the
manufacturer’s recommendations. Incubation media contained
60 mM live cell Renilla substrate Endu-Ren (Promega) and BFA
where indicated. Control samples contained an equivalent amount
of DMSO, used as solvent for BFA. Renilla light signal was
recorded with SpectraMax M5 multi-well plate reader (Molecular
Devices). Each point on a graph is an average of measurements
obtained from at least 16 wells.
siRNA
GBF1 siRNA CAACACACCUACUAUCUCU was obtained
from Dharmacon. Silencer Negative control #1 siRNA was
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in a 96-well plate, transfected the next daywith Dharmafect1
transfection reagent (Dharmacon) according to the manufacturer’s
recommendations and incubated for 3 more days before the polio
replication experiments.
BFA toxicity assay
HeLa cells were plated at 20 000 per well in a 96-well plate and
transfected with plasmids with Lipofectamine LTX (Invitrogen)
according to the manufacturer’s recommendations. The next day
the medium was supplemented with 100 ng/ml of BFA and the
cells were incubated for two more days with medium change
approximately every 8 hours to ensure constant presence of the
inhibitor. Cell viability was assessed with CellTiter-Glo lumines-
cent cell viability assay kit (Promega).
Secretion rescue assay
HeLa cells in a 96 well plate were transfected with pGEM-3Z
(control), pYFP-GBF1 wt, or pYFP-GBF1 A795E and pCMV-
Gluc vector (4:1 mass ratio). The next day the cells were washed
with serum-free medium and incubated with BFA (1 mg/ml) or
DMSO for 5 h in normal growth medium (75 ml/well). A portion
(20 ml) of the medium from each well was assayed with 20 mlo f
Gaussia Luciferase assay solution (New England Biolabs).
In vitro translation
HeLa S10 extracts for translation reactions were prepared as
described [43] but were not treated with micrococcal nuclease.
Translation reaction mixtures of 50 ml included 2.5 mg of RNA
transcripts. An aliquot of 9 ml from each reaction mixture was
mixed with 1 ml of Redivue VIral methionine (Amersham) and
incubated for 3.5 h at 34uC, after which one-fourth of the material
was resolved by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) mini-gel for visualization of translation
products. The remaining 40 ml were also incubated for 3.5 h at
34uC and then centrifuged for 20 min at 16,0006g at 4uC. Pellets
were assayed by Western blot with the ECL Advance system
(Amersham) according to the manufacturer’s recommendations.
Vaccinia T7 expression system
For electron microscopy. HeLa cells were plated in a 12-well
plate with Thermanox plastic coverslips (Nalge Nunc) at
200 000 cells/well, one day prior to infection with vaccinia virus
VT7-3, expressing T7 RNA polymerase [62] at a multiplicity of 10
PFU/cell. After one hour the cells were transfected with plasmids
with Lipofectamine LTX (Invitrogen) and incubated for 4.5 hours.
Cells were then washed with PBS and placed in fixative (2.5%
glutaraldehyde/4%paraformaldehydein0.1 M sodiumcacodylate
buffer) and stored at 4uC. Transmission electron microscopy was
performed at Rocky Mountain Laboratory (NIAID NIH).
For immunofluorescent microscopy. HeLa cells were
plated on coverslips in a 12-well plate at 200 000 cells/well, one
day prior to Lipofectamine LTX transfection with a 4:1 mass
mixture of pArf1-EGFP and pTM-2A-39, respectively. After
16 hours incubation, the cells were infected at 10 PFU/cell with
vaccinia VT7-3 virus for 1 hour and than incubated for 4.5 hours
and processed for immonofluorescent microscopy.
For replication assay. HeLa cells were plated in a 96-well
plate at 20 000 cells/well. Vaccinia infection and DNA transfection
wereperformed essentially thesamewayasfor electronmicroscopy,
but the cells were transfected with linearized plasmids pXpA-RenR
or pXpA-RenRD3D. Where indicated, inhibitors were added
simultaneously with plasmid transfection. The cells were incubated
for 4.5 hours, the medium was changed to include 60 mM Endu-
Ren live cell Renilla substrate (Promega) and inhibitors where
indicated. Renilla light signal was recorded with a SpectraMax M5
multi-well plate reader (Molecular Devices).
Immunofluorescent microscopy
Cells grown on glass coverslips were fixed with 4% parafor-
maldehyde-phosphate-buffered saline (PBS) for 20 min, washed
with PBS 3 times and stored in PBS at 4uC. Before staining the
cells were permeabilized with 0.2% Triton X-100 in PBS for
5 min and washed 3 times with PBS. The cells were then
incubated in 3% nonfat dry milk solution for 1 h to block
nonspecific binding sites. This solution also was used for dilution of
primary and secondary antibodies in which cells were sequentially
incubated for 1 h. 10 ng/ml of Hoechst 33342 was added to the
first blocking solution to stain nuclear chromatin. Images were
taken with Leica DMIRE microscope. Digital images were
processed with Adobe Photoshop software.
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